StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
TYRABullishEarningsnews
High materiality8/10

TYRA Advances Dabogratinib 3x3 Path With Data Milestones and Cash Runway

Aug 4, 2026, 4:09 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Upcoming data readouts (Sept 2026 SURF302; early-2027 BEACH301) and a strengthened balance sheet via a larger ATM capacity could drive a re-rating if data are favorable, though Phase 2 results carry typical execution risk and dilution concerns from ATM activity.

AI summary

What happened, with direct paths to the underlying reporting

TYRA reported Q2 2026 results and highlighted Dabogratinib progress across SURF303, SURF302, and BEACH301. Sept 2026 will bring SURF302 initial data, with BEACH301 sentinel results targeted by end-2027. A new EVP, Jonathan Day, was appointed to accelerate skeletal dysplasia programs; TYRA also reiterated a cash runway into 2H-2028 with $353.9M on hand.

  • SURF302 Ph2 data due Sept 2026; enrollment >40.
  • BEACH301 sentinel results end of Q1 2027; fifth dose level opened; ~25 children.
  • Jonathan Day appointed EVP, Clinical Development to lead skeletal dysplasia strategy.
  • Cash, cash equivalents and marketable securities: $353.9M; runway into 2H 2028.
  • Dabogratinib 3x3 strategy targets 3 Phase 2 pivotal studies: LG-UTUC, IR NMIBC, ACH.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event